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ABSTRACT 
The relentless discovery of cancer biomarkers demands improved methods for their detection. In this work, we developed protein imprinted 
polymer on three-dimensional gold nanoelectrode ensemble (GNEE) to detect epithelial ovarian cancer antigen-125 (CA 125), a protein biomarker 
associated with ovarian cancer. CA 125 is the standard tumor marker used to follow women during or after treatment for epithelial ovarian cancer. The 
template protein CA 125 was initially incorporated into the thin-film coating and, upon extraction of protein from the accessible surfaces on the thin film, 
imprints for CA 125 were formed. The fabrication and analysis of the CA 125 imprinted GNEE was done by using cyclic voltam- metry (CV), 
differential pulse voltammetry (DPV) and electrochemical impedance spectroscopy (EIS) techniques. The surfaces of the very thin, protein imprinted 
sites on GNEE are utilized for immunospe- cific capture of CA 125 molecules, and the mass of bound on the electrode surface can be detected as a 
reduction in the faradic current from the redox marker. Under optimal conditions, the developed sensor showed good increments at the studied 
concentration range of 0.5–400 U mL−1 . The lowest detection limit was found to be 0.5 U mL−1 . Spiked human blood serum and unknown real serum 
samples were analyzed. The presence of non-specific proteins in the serum did not significantly affect the sensitivity of our assay. Molecular 
imprinting using synthetic polymers and nanomaterials provides an alternative approach to the trace detection of biomarker  proteins. 
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1. Introduction 
 
Ovarian cancer is one of the most frequent cancers among 
women, and it leads to more deaths than any other type of female 
reproductive cancer. Ovarian cancer is a cancer that forms in the tis- 
sues of the ovary. Most ovarian cancers are either ovarian epithelial 
carcinomas or malignant germ cell tumors. Ovarian cancer symp- 
toms are often vague. The majority of ovarian cancers are detected 
at a late stage resulting in high mortality rates. Thus, it is essen- 
tial to develop inexpensive and simple methods for early diagnosis 
(Geurts et al., 2011; Zhu et al., 2011). Over a decade of omics inves- 
tigations have identified many potential biomarkers for ovarian 
cancer but only a few are currently used in the clinic. Early Detection 
Research Network (EDRN), a program run by the National Can- 
cer Institute (NCI), released its evaluation of the performance of 
35 previously reported markers of ovarian cancer (Cramer et al., 
2011). They also stated that many of these markers claimed to be 
better than CA 125 (cancer antigen 125), one of only two mark- 
ers approved for monitoring ovarian cancer. A cancer antigen    125 
 
 
 
(CA 125) is a protein found on the surface of many ovarian cancer 
cells (Peng et al., 2011). When the researchers measured the mark- 
ers in 180 diseases, and 660 control specimens obtained as part of 
NCI’s Prostate, Lung, Colorectal & Ovarian Cancer Screening Trial, 
none of the new markers was better than CA 125, after all (Arnaud, 
2011). Normal blood levels are usually less than 35 U mL−1 (units 
per milliliter). More than 90% of women have high levels of CA 
125 when the cancer is advanced. CA 125 levels are also elevated 
in about half of women whose cancer has not spread outside of 
the ovary. If the CA 125 level is increased at the time of diagnosis, 
changes in the CA 125 level can be used during treatment to get an 
idea of how well it is working. This is why CA 125 has been studied 
as a screening test. 
In general, a number of high-performing protein detection 
protocols are under development (Wang and Yau, 2011), and 
many of the most specific and sensitive use micro- and nano- 
materials in their sensing schemes (Perfezou et al., 2012). Gold 
nanomaterials (Ho et al., 2010; Wei et al., 2011), carbon nanotubes 
(Viswanathan et al., 2009; Yu et al., 2006), barcoded nanoparticles 
(Lin et al., 2011; Yu et al., 2006), nanowire transistors (Ionescu, 
2010), enzyme-labeled beads (Mani et al., 2009; Rissin et al., 
2010), micro-nanoarrays (Das and Kelley, 2011) and microfluidic 
immunoarrays (Chen et al., 2009; Chikkaveeraiah et al., 2011) used 
 
  
 
 
Fig. 1. Schematic representation of molecular imprinted protein nanosensor fabrication and template protein detection. Step1 – adsorption of CA 125 on to the nanoelectrodes 
surface; Step 2 – electrochemical polymerization of phenol; Step 3 – template protein removal; Step 4 – CA 125 binding and signal  generation. 
 
with electrochemical transduction all reveal eminent capability for 
the development of cancer biomarker detection. Current analyti- 
cal methods are in general cumbersome or time-consuming; they 
usually assay a single protein; are often costly; and, in the case 
of antibody-based assays, there are occasional concerns stemming 
from the cross-reactivity of the detecting antibody. Still challenges 
remain, however, pertaining to the development of simple analy- 
sis systems that are cost-effective and robust enough for clinical 
use. 
Molecular imprinting (MI) technology provides considerable 
potential as a cost-effective alternative to the use of biomolecule 
based recognition in a variety of sensor applications (Cai et al., 
2010). Molecular imprinting is a technique that creates synthetic 
materials containing specific receptor sites having a high affinity 
for a target molecule. Molecular imprinted polymers (MIPs) are 
crosslinked polymers, which are synthesized in the presence of 
template molecules. Three-dimensional cavities are created within 
a polymeric matrix that is complementary to the size, shape, and 
functional group orientation of the target molecule. The imprinted 
polymer cavity allows the target molecules to occupy the cavity 
space, while the functional group orientation within the cavity will 
preferentially bind in specific locations to only the target molecule. 
Deposition of MIPs onto the surface of nanostructures improves 
sensitivity for the recognition of a range of organic compounds. 
Whitcombe et al. (2011) extensively reviewed many methods used 
for imprinting recognition for protein targets in polymers and their 
incorporation with a number of transducer platforms with the 
aim of identifying the most promising approaches for the prepa- 
ration of MIP-based protein sensors Protein imprinted polymers 
(Whitcombe et al., 2011). Recently Wang et al. developed a surface 
molecular imprinting using self-assembled monolayers to design 
sensing elements for the detection of CEA cancer biomarker (Wang 
et al., 2010). 
Electrodics at microscopic and nanoscopic dimensions consti- 
tutes one of the frontiers in electrochemical science. The micro 
or nanoelectrode ensembles have been used for the development 
of electrochemical sensors. They offer numerous benefits over the 
conventional macroelectrodes such as enhanced mass transport, 
lowered influence of the solution resistance, low detection limit, 
and better signal-to-noise ratio (S/N). In principle, the electroana- 
lytical detection limits at a nanoelectrode ensemble will be much 
lower than that at an analogous macro sized electrode because 
the ratio of faradic to the capacitive current is significantly high 
at ensemble electrodes. The colloidal chemical approach has been 
conveniently used for the development of ultramicroelectrodes and 
nanoelectrode ensembles (Kumar Jena and Retna Raj, 2008). 
In the present investigation, considering the importance of the 
detection of CA 125 biomarker in blood serum, we have explored 
the possible utilization of the molecular imprinted gold nanoelec- 
trode ensembles (MIPGNEE) for the determination of CA 125. Fig. 1 
depicts the outline of an analytical technique that we developed for 
the determination of CA 125. 
 
2. Experimental 
 
2.1. Reagents 
 
CA 125 antigen was obtained from Abcam, UK. Human blood 
serum is collected  from  healthy  and  infected  female  volun- 
teers. All other reagents human serum albumin (HSA), potassium 
ferricyanide (K3[Fe(CN)6]), potassium ferrocyanide trihydrade 
(K4[Fe(CN)6]), phenol, and acetic acid, sodium dodecyl sulfate and 
other chemicals and solvents were purchased from  Sigma–Aldrich. 
 
2.2. Preparation of the gold nanoelectrode ensembles 
 
Gold nanoelectrode ensembles were prepared by using electro- 
less deposition of the gold within the 50 nm pores of polycarbonate 
particle track-etched membranes. A simple controlled solvent 
etching procedure based on the solubility of polycarbonate mem- 
branes in solvent mixtures is adopted for the fabrication of the 3D 
GNEE (Krishnamoorthy and Zoski, 2005). Please refer Supporting 
information for detailed experimental method. SEM images were 
obtained using a scanning electron microscope (JEOL, Model FEI 
Quanta 400FEGESEM/EDAX PEGASUS X4M). 
 
2.3. Electrochemical measurements 
 
All electrochemical experiments were carried out using an Auto- 
lab PGSTAT 12, potentiostat/galvanostat with a three-electrode 
electrochemical system was configured by connecting gold nano- 
electrode ensamples, an Ag/AgCl reference electrode and a 
platinum wire as auxiliary electrode. A 2 mm diameter hole was 
punched in a piece of Teflon®  adhesive tape with a thickness of 
0.08 and then pasted onto the membrane so that the exposed cop- 
per tape was also sealed on both sides to prevent exposure to the 
electrolyte solution. Electrochemical impedance spectroscopy (EIS) 
was used to monitor impedance changes of the electrode surface 
and its interface to the electrolyte containing 0.5 mM K3[Fe(CN)6], 
1.5 mM K4[Fe(CN)6], in 0.1 M phosphate buffer solution (PBS) at pH 
7.4. An a.c. sine-wave voltage was applied to the working elec- 
trode with a superimposed d.c. voltage at 0.200 mV. The AC voltage 
  
amplitude used was 10 mV, and the equilibrium time was 10 min. 
The frequency varied from 1 Hz to 1 MHz. The impedance data were 
then represented in the form of Nyquist plots, which were fitted to 
an equivalent circuit by the analysis function in Nova (Autolab) soft- 
ware. Differential pulse voltammetry (DPV) was conducted in 0.1 M 
PBS (pH 7.4) containing 0.5 mM K3[Fe(CN)6], 0.5 mM K4[Fe(CN)6] 
and 0.1 M KCl. The initial and final potentials versus the reference 
electrode were 0.0 and 0.5 V, respectively. The modulation ampli- 
tude was 50 mV, and the modulation time 0.05 s; the step potential 
was 2 mV and the interval time 0.1 s. 
 
2.4. Electropolymerization of phenol on nanoelectrode surface 
 
Polyphenol (PP) film was electropolymerized on the exposed 
nanoelectrode surface by cyclic voltammetry (CV) in phosphate 
buffered saline (PBS) containing 2 mM phenol (pH 7.4). To the work- 
ing electrode a ‘ramping’ voltage was applied at a scanning rate of 
50 mV s−1 between 0.0 and 0.9 V versus (Ag/AgCl) for 10 cycles. To 
entrap template proteins in the PP coating, GNEE was incubated 
with 50 µL of 400 U mL−1 CA 125 in pH 7.4 at 4 ◦C for 15 min fol- 
lowed by application of 10 cycles of voltage scanning, as described 
above. CA 125 molecules were adsorbed on GNEE by physisorption 
due to electrostatic and hydrophobic interactions between the CA 
125 and the surface of GNEE. 
 
2.5. Protein imprinted electrode preparation 
 
For protein imprinted electrode preparation, the nanoelectrode 
surface with protein-entrapped PP coating was rinsed and incu- 
bated overnight in deionized water at room temperature. In some 
instances, a developing buffer containing 1% acetic acid and 3% 
sodium dodecyl sulfate was used, which resulted in higher protein 
extraction efficiency (Cai et al., 2010). After protein entrapment 
and removal, the sample was evaluated by EIS. Before measuring 
template protein rebinding, DPV was repetitively performed in a 
template-protein-free buffer solution until the current stabilized. 
Nanosensor responses were then measured by DPV or EIS follow- 
ing incubation for 30 min at room temperature with the CA 125 at 
various  concentrations. 
 
2.6. Assay procedure 
 
The MIPGNEE was incubated for 30 min at 25 ± 3 ◦C with 20 µL of 
the CA 125 standard or spiked or real samples followed by washing 
with PBS (0.05 M, pH 7.0). The DPV was recorded as described pre- 
viously. The electrode was regenerated by extraction of bound CA 
125 protein from imprinted binding cavities was done by washing 
with deionized water at room temperature. 
 
2.7. Serum collection 
 
Blood serum samples were prepared by collecting venous blood 
samples from female volunteers in BD Vacutainer® SSTTM GEL 
Tubes (Becton Dickinson, India). The SST tubes were allowed to 
clot, and the tubes were centrifuged at 1300 × g. The separated 
serum was decanted for use. The same procedures were followed 
for serum samples from healthy  personals. 
 
2.8. Safety notes 
 
Clinical serum samples are biohazardous should be handled 
with care. Carcinogenic organic solvents and toxic chemicals such 
as phenol were used in this study and should be handled with 
care. 
 
 
 
Fig. 2.  Scanning electron microscopy image of a gold nanoelectrode    ensembles. 
 
 
3. Results and discussions 
 
3.1. Electrode fabrication 
 
Scanning Electron Microscopy (SEM) surface image of the 
membrane shows gold nanowires  with  an  average  diameter  of 
50 nm and a length of 180 ± 20 nm was shown in Fig.  2.  It 
indicates the absence  of  voids  on  the  surface,  indicating  that 
this method  efficiently  produces  3D  GNEEs  with protruding 
gold  wires.  Based  on  this  image  the  nanowires  density        was 
found  to  be  ∼6 nanoelectrodes µm−2,  which  is  in  accordance 
with the declared pore density, thus confirming that each tem- 
plate pore was filled with gold. A good electronic conduction 
was established between the nanoelectrode ensembles and the 
copper tape when the GNEE was connected to the external cir- 
cuit. The results of energy dispersive X-ray (EDX) measurements 
evidenced that the used procedure minimized chemical contami- 
nation from the gold deposition process during the preparation of 
the GNEEs. 
 
3.2. Protein imprinting studies 
 
CA 125 is a high molecular weight, non-mucinoid glycoprotein 
(M.W. 200 kDa approx.) which is made up of about 25% carbo- 
hydrate. CA 125 protein imprints were made by pre-adsorbed 
template proteins on the  nanoelectrodes  to  entrap  within the 
PP coating. The template protein CA 125 was initially incorpo- 
rated into the thin film coating and, upon extraction of protein 
creates the accessible surfaces on the thin film, sensor electro 
chemical impedance was found to be greatly reduced due to 
electrical leakage through the surface imprinted sites in the PP 
film on GNEE. Subsequent recognition of the template protein 
was detected as an increase in impedance due to the relatively 
lower conductivity of the protein (Cai et al., 2010). A critical 
component for the assembly of the sensor design comprised 
electropolymerizing a nonconductive polyphenol (PP) nanocoat- 
ing onto the nanoelectrodes. The deposition was self-limiting 
and yielded a highly conformal nanocoating that is beneficial 
in low-noise recordings (Fig. S1). The peak current (around at 
1.6 V) of phenol polymerization at first cycle was significantly 
varied with the concentration of CA 125 used for adsorption on 
  
 
 
Fig. 3. (a) Cyclic voltammogram of nonimprinted GNEE (NIPGNEE), MIPGNEE at first cycle of polymerization and subtracted volatmmogram. (b) Nyquist plots of bare GNEE, 
MIPGNEE incubated with CA 125 400 U mL−1  and HSA 10−2 mg mL−1  (frequency scanned from 1 Hz to 1 MHz). 
 
GNEE. The peak current was decreased from 50 to 300 U mL−1 
of CA 125, with further increase in the CA 125 concentration 
to 300–400 U mL−1, the significant decrease of the charge was 
not observed (inset Fig. S1(a)). So, 300 U mL−1 was taken as 
optimum template protein concentration for imprint polymeriza- 
tion. 
Estimation of the number of CA 125 imprints was calculated 
by difference between the integrated charge for the electrochem- 
ical polymerization at bare GNEE and CA 125 absorbed GNEE. For 
these experiments, the GNEE were coated with only PP or CA 125 
entrapped PP. First CV scan cycle of PP electropolymerization on 
GNEE and CA 125-GNEE is shown in Fig. 3a. A significant cur- 
rent loss was observed for the CA 125 adsorbed electrode. PP was 
not deposited in CA 125 adsorbed sites, we converted the charge 
difference to the volume of PP and then the amount of CA 125 
imprints according to the dimensions of the CA 125 molecule. 
According to the voltammogram, the charge difference of imprint 
was 5.72 µC, while the charge due to without imprint protein and 
with imprint was 41.13 µC and 37.99 µC respectively. Scan cycle 
number 10 was considered as residual background current and 
was subtracted. Therefore, the imprints contributed charge   was 
5.72 µC which is equivalent to the amount of protein adsorbed or 
imprint sites. The area of imprint was calculated using the following 
equation. 
The volume of PP (VPP) was calculated from the following equa- 
tion (Cai et al., 2010): 
 
Therefore, the total amount of imprints (NMI) was: NMI = 
VPP/VCA125  = 1.17 × 10
9.     Nanoelectrodes     density      NGNEE  = 
6 nanoelectrode µm−2. Therefore the number of  nanoelectrodes 
on working electrode (2 mm diameter) = 1.88 ×  107. 
So the  number  of  protein  imprints  on  each  nanoelec- 
trode = NMI/NGNEE = 62.3. 
The detection of CA 125 binding to its imprinted site was evalu- 
ated using EIS. Nyquist plots show the impedance spectroscopy of 
the MIPGNEE sensor at different stages of development of MIPGNEE 
(Fig. 3b). The bare GNEE electrode exhibited almost the straight 
line in Nyquist plots, which is characteristic for a diffusion limit- 
ing step of electrochemical process (Fig. 3b). However, MIPGNEE 
showed a semicircle plot at higher frequencies. It indicated that 
the electrode redox processes mass transfer was the electron- 
transfer limited. The electron transfer kinetics on the electrode 
surface originates from the formation of ion transfer channels 
caused by protein imprinted sites. MIPGNEE yielded higher resis- 
tance for the interfacial electron transfer upon incubation with 
400 U mL−1 of CA 125. However, 10−2 mg mL−1 of HSA did not exert 
a significant impedance change. These EIS measurements revealed 
that the MIPGNEE had the good selectivity and sensitivity for CA 
125. 
 
3.3. Analytical calibration 
 
The analytical calibration for CA 125 was conducted to deter- 
mine the sensitivity of the MIPGNEE sensor to CA 125, and the 
MIPGNEE were tested with different concentrations of CA 125 in 
=  
PBS pH 7.4. The calibration curve for the voltammetric detection 
m is the molecular weight of phenol, QGNEE is the total charge dif- 
ference generated during the deposition, F is the Faradic constant 
and cr is the density of phenol and equals to 1 mg mm−3, k is the 
correction coefficient (Cai et al.,   2010). 
In these experiments, the volume of PP (VPP) corresponds to: 
(94.1 × 5.72 × 10−6) 
(9.1 × 6.02 × 1023 × 1.6 × 10−19 × 10−3) 
= 6.14 × 10−7 mm3 
 
CA 125 is a glycoprotein with a molecular weight of ∼200 kDa. 
Hence, assuming the size of CA 125  is  ∼10 nm  diameter  and 
made the following calculation  to  measure  approximate number 
of imprints on the  sensor. 
of CA 125 was carried out by recording, for each concentration, 
the response of a MIPGNEE at optimum experimental conditions 
(Fig. 4). Each point of the calibration graph corresponds to the 
mean value obtained from 5 independent measurements. The limit 
of detection (LOD) was defined as the lowest concentration of 
biomarker producing a peak current 3 times higher than the stan- 
dard deviation of the peak current in the absence of CA 125 under 
identical conditions. A sigmoidal curve for the current variation was 
observed over the range 1–400 U mL−1 with LOD 0.5 U mL−1. Repli- 
cated analysis for CA 125 (10 U mL−1) led to a standard deviation 3.1 
for 5 independent analyses. It indicated that the imprinted sensor 
response and fabrication procedure were reproducible. MIPGNEE 
were regenerated up to 20 cycles without significant loss its effi- 
ciency (Fig. S2). The interference protein response on the MIPGNEE 
was shown in inset Fig. 4c. It clearly indicates the absence of sig- 
nificant interferes on CA 125 determination. 
PP  = V 
  
Table 1 
Determination of CA 125 present in spiked and real human serum samples. 
 
 
 
 
 
 
 
 
 
 
Fig. 4. CA 125 concentration-dependent peak current response represented as the 
percentage of peak current (%) versus concentration (U mL−1 ) on semi log plot. Inset 
(a), DPV current responses to CA 125. Inset (b), DPV current responses to different 
HSA concentrations. 
 
3.4. CA 125 in human serum samples 
 
Direct determination of serum CA 125 level is very important 
in the early detection of ovarian cancer. Human serum samples 
were spiked with known amount CA 125 and analyzed for method 
validation. The accuracy of the CA 125 determination was exam- 
ined by comparison of the results obtained by this method with 
those from the ELISA CA 125 analysis kit (BioCheck, Inc., CA). The 
CA 125 contents in unknown real serum samples were also quanti- 
fied with both techniques. All results were given in Table 1. These 
results of both methods were thus in good agreement. Experimen- 
tal results revealed that the proposed imprinted sensor showed 
better sensitivity, recovery with   reproducibility. 
 
4. Conclusions 
 
In conclusion, the performance and clinical utility of CA 125 
molecular imprinted nanoelectrodes sensor were analyzed. The 
integration of the molecular imprinting technology and nanotech- 
nology meets the demand of facilitating the electrochemical sensor 
detection levels. The gold nanoelectrodes ensembles improve the 
performance of the electrochemical reaction of substrate and 
increase the sensitivity of the CA 125 detection. This developed sen- 
sor showed good reproducibility in human serum samples. Serum 
testing using proposed biosensor is simple, making it an attractive, 
effective alternative to conventional ELISA testing, and the possi- 
bility of developing home testing kits would further facilitate it 
as a diagnostic aid, enabling patients to monitor their own health 
at home and is important for those who live far from their treat- 
ment centers. Summarily, the proposed method had potential to be 
further developed for practical clinic cancer diagnosis. 
 
 
 
 
 
 
 
 
 
 
Acknowledgements 
 
We  thank  Dr.  R.  Vengatesan,  (Dental  surgeon)  for  his  much 
appreciated   support   and   care   during   sample   collection.   We 
also  thank  the  volunteers  who  participated  in  this  study.  The 
authors  acknowledge  the  financial  support  from  Fundac¸ ão  para 
a Ciência e Tecnologia, Portugal (Project reference no. PTDC/SAU- 
ENB/114786/2009). 
 
Appendix A. Supplementary data 
 
Supplementary data associated with this article can be found, in 
the online version, at doi:10.1016/j.bios.2011.12.049. 
 
References 
 
Arnaud, C.H., 2011. Chem. Eng. News 89 (30), 40–43. 
Cai, D., Ren, L., Zhao, H., Xu, C., Zhang, L., Yu, Y., Wang, H., Lan, Y., Roberts, M.F., 
Chuang, J.H., Naughton, M.J., Ren, Z., Chiles, T.C., 2010. Nat. Nanotechnol. 5 (8), 
597–601. 
Chen, H., Jiang, C., Yu, C., Zhang, S., Liu, B., Kong, J., 2009. Biosens. Bioelectron. 24 
(12),   3399–3411. 
Chikkaveeraiah, B.V., Mani, V., Patel, V., Gutkind, J.S., Rusling, J.F., 2011. Biosens. 
Bioelectron. 26 (11), 4477–4483. 
Cramer, D.W., Bast Jr., R.C., Berg, C.D., Diamandis, E.P., Godwin, A.K., Hartge, P., Lok- 
shin, A.E., Lu, K.H., McIntosh, M.W., Mor, G., Patriotis, C., Pinsky, P.F., Thornquist, 
M.D., Scholler, N., Skates, S.J., Sluss, P.M., Srivastava, S., Ward, D.C., Zhang, Z., Zhu, 
C.S., Urban, N., 2011. Cancer Prev. Res. 4 (3),    365–374. 
Das, J., Kelley, S.O., 2011. Anal. Chem. 83 (4), 1167–1172. 
Geurts, S.M.E., de Vegt, F., van Altena, A.M., van Dijck, J.A.A.M., Tjan-Heijnen, 
V.C.G., Verbeek, A.L.M., Massuger, L.F.A.G., 2011. Int. J. Gynecol. Cancer 21 (5), 
837–845. 
Ho, J.-a.A., Chang, H.-C., Shih, N.-Y., Wu, L.-C., Chang, Y.-F., Chen, C.-C., Chou, C., 2010. 
Anal. Chem. 82 (14), 5944–5950. 
Ionescu, A.M., 2010. Nat. Nanotechnol. 5 (3), 178–179. 
Krishnamoorthy, K., Zoski, C.G., 2005. Anal. Chem. 77 (15), 5068–5071. 
Kumar Jena, B., Retna Raj, C., 2008. Anal. Chem. 80 (13), 4836–4844. 
Lin, J., Wei, Z., Mao, C., 2011. Biosens. Bioelectron. 29 (1), 40–45. 
Mani, V., Chikkaveeraiah, B.V., Patel, V., Gutkind, J.S., Rusling, J.F., 2009. ACS Nano 3 
(3),   585–594. 
Peng, N.-J., Liou, W.-S., Liu, R.-S., Hu, C., Tsay, D.-G., Liu, C.-B., 2011. Cancer Biother. 
Radiopharm. 26 (2), 175–181. 
Perfezou, M., Turner, A., Merkoci, A., 2012. Chem. Soc. Rev., 
doi:10.1039/C1CS15134G. 
Rissin, D.M., Kan, C.W., Campbell, T.G., Howes, S.C., Fournier, D.R., Song, L.,   Piech, 
T., Patel, P.P., Chang, L., Rivnak, A.J., Ferrell, E.P., Randall, J.D., Provuncher, G.K., 
Walt, D.R., Duffy, D.C., 2010. Nat. Biotechnol. 28 (6), 595–599. 
Viswanathan, S., Rani, C., Anand, A.V., Ho, J.-a.A., 2009. Biosens. Bioelectron. 24 (7), 
1984–1989. 
Wang, J., Yau, S.-T., 2011. Biosens. Bioelectron. 29 (1),  210–214. 
Wang, Y., Zhang, Z., Jain, V., Yi, J., Mueller, S., Sokolov, J., Liu, Z., Levon, K., Rigas, B., 
Rafailovich, M.H., 2010. Sens. Actuators B-Chem. 146 (1), 381–387. 
Wei, Q., Zhao, Y., Xu, C., Wu, D., Cai, Y., He, J., Li, H., Du, B., Yang, M., 2011. Biosens. 
Bioelectron. 26 (8), 3714–3718. 
Whitcombe, M.J., Chianella, I., Larcombe, L., Piletsky, S.A., Noble, J., Porter, R., Horgan, 
A., 2011. Chem. Soc. Rev. 40 (3), 1547–1571. 
Yu, X., Munge, B., Patel, V., Jensen, G., Bhirde, A., Gong, J.D., Kim, S.N., Gillespie, J., 
Gutkind, J.S., Papadimitrakopoulos, F., Rusling, J.F., 2006. J. Am. Chem. Soc. 128 
(34),     11199–11205. 
Zhu, C.S., Pinsky, P.F., Cramer, D.W., Ransohoff, D.F., Hartge, P., Pfeiffer, R.M., Urban, 
N., Mor, G., Bast Jr., R.C., Moore, L.E., Lokshin, A.E., McIntosh, M.W., Skates, S.J., 
Vitonis, A., Zhang, Z., Ward, D.C., Symanowski, J.T., Lomakin, A., Fung, E.T., Sluss, 
P.M., Scholler, N., Lu, K.H., Marrangoni, A.M., Patriotis, C., Srivastava, S., Buys, S.S., 
Berg, C.D., Team, P.P., 2011. Cancer Prev. Res. 4 (3), 375–383. 
Source Proposed sensor    Reference method ELISA   
 Added (U mL−1 ) Found (U mL−1 ) Std. dev. (n = 5)  Found (U mL−1 ) Std. dev. (n = 5) 
Spiked blood 10 9 2.5  12 3.8  
serum samples 50 45 6.4  41 7.5  
 100 96 8.4  98 9.3  
Infected patient - 85 7.9  76 8.3  
Healthy person - 17 4.4  15 3.6  
 
